CompletedEarly Phase 1NCT01959477
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
Studying Lymphomatoid granulomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Case Comprehensive Cancer Center
- Principal Investigator
- Brian Hill, MDCase Comprehensive Cancer Center
- Intervention
- busulfan(drug)
- Enrollment
- 33 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2014 – 2015
Study locations (1)
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01959477 on ClinicalTrials.gov